Charles River Labs, US1591881009

The PathoProof Mastitis PCR Assays - Charles River Labs bets on rapid dairy diagnostics

02.07.2026 - 19:05:38 | ad-hoc-news.de

PathoProof Mastitis PCR Assays from Charles River Labs bring multiplex PCR testing to dairy herds with results in hours instead of days. Anyone holding Charles River Labs stock (NYSE: CRL, ISIN US1591881009) should know this product.

Charles River Labs, US1591881009
Charles River Labs, US1591881009

By Daniel Foster, ad hoc news Software & Services Desk. Reviewed July 02, 2026, 1:15 PM ET. Details in the imprint.

PathoProof Mastitis PCR Assays sit in a chilled rack next to a benchtop thermocycler, tiny reaction tubes labeled in fine marker ink and a faint chemical smell in the air. A lab tech in a navy fleece clicks through the software, and within a few hours a dairy farmer knows exactly which mastitis-causing pathogens are hitting their herd.

Fast diagnostics for dairy herds

Charles River Labs markets PathoProof Mastitis PCR Assays as a veterinary molecular diagnostic panel designed to detect multiple mastitis pathogens in bovine milk samples using real-time PCR. The assays help veterinarians and dairy producers identify specific bacteria behind clinical or subclinical mastitis, enabling more targeted treatment and reduced unnecessary antibiotic use.

The PathoProof portfolio typically includes panels covering key pathogens such as Staphylococcus aureus, Streptococcus agalactiae, Streptococcus uberis, Escherichia coli, and other common mastitis agents, all run from a single milk sample. Because results can be available the same day the sample is processed, farms can adjust therapy and management faster than with traditional culture methods, which often require 24 to 48 hours of incubation.

Dig deeper

Charles River Labs diagnostics for investors

Learn more about how veterinary and food diagnostics like PathoProof Mastitis PCR Assays fit into the broader business of Charles River Labs stock.

How PathoProof assays work

At the core, PathoProof Mastitis PCR Assays use multiplex real-time PCR technology, where multiple sets of primers and probes target different bacterial DNA sequences in the same reaction. When the instrument runs the temperature cycles, fluorescence signals from each probe reveal the presence or absence of particular pathogens, giving a detailed pathogen profile for each milk sample.

In practice, a veterinarian or dairy lab collects milk aseptically from affected quarters, prepares the sample according to the kit instructions, and loads it into the PCR plate or tubes. The assay protocol defines cycling parameters, reagent volumes, and quality controls, usually including positive and negative controls to ensure assay validity. Once the run finishes, the software interprets Ct values and flags which pathogens are detected above threshold.

US and global footprint

While Charles River Labs is widely known among US investors for its preclinical CRO work, its PathoProof Mastitis PCR portfolio sits in a more specialized veterinary diagnostics niche that still touches US agriculture. Large US dairy operations and veterinary clinics with molecular capability can integrate PathoProof assays into herd health programs, especially where rapid pathogen differentiation supports antimicrobial stewardship commitments.

These kits are also relevant in Europe and other high-milk-production regions, where mastitis remains one of the costliest diseases in dairy cattle and regulators scrutinize antibiotic use. Charles River Labs positions the assays as a way to tighten disease management, improve milk quality, and support compliance with residue and animal welfare standards, giving the product a cross-border appeal in the dairy sector.

Business context and stock angle

PathoProof Mastitis PCR Assays do not dominate earnings headlines, but they sit in Charles River Labs' broader life sciences and diagnostic offerings that help diversify beyond core contract research services. For US retail investors watching agricultural and veterinary diagnostics, the product is a reminder that the company reaches into practical, recurring-use tools that intersect with food supply and animal health. Charles River Labs stock (NYSE: CRL) reflects the entire mix, from sophisticated biopharmaceutical services to niche assay portfolios like PathoProof.

Key facts at a glance

  • Product: PathoProof Mastitis PCR Assays
  • Manufacturer: Charles River Laboratories International, Inc.
  • Category: Software/Service/Subscription (diagnostic assays and workflow)
  • Launch: Available as part of Charles River Labs' veterinary diagnostic portfolio; specific launch dates may vary by panel.
  • MSRP / Price: Pricing typically arranged through Charles River Labs sales channels and veterinary distributors; per-kit pricing may vary by region and panel configuration.
  • Availability: Distributed to veterinary laboratories and dairy operations in multiple regions, including the US, subject to local regulatory and purchasing arrangements.
  • Target audience: Veterinary diagnostic labs, dairy herd veterinarians, and larger dairy producers needing rapid mastitis pathogen identification.
  • Standout / USP: Multiplex real-time PCR detection of multiple mastitis pathogens from a single milk sample, allowing same-day, pathogen-specific treatment decisions compared with traditional culture turnaround.

Find PathoProof Mastitis PCR Assays on social

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.

en | US1591881009 | CHARLES RIVER LABS | boerse | 69675195 | bgmi